The United Arab Emirates’ decision to quit OPEC has blindsided its partners and will dilute the cartel’s ability to manage oil prices by adjusting supply. Bloomberg’s Stephen Stapczynski explains how differences in the vision of the UAE and the group’s de facto leader Saudi Arabia have simmered for years.
The United Arab Emirates’ decision to quit OPEC has blindsided its partners and will dilute the cartel’s ability to manage oil prices by adjusting supply. Bloomberg’s Stephen Stapczynski explains how differences in the vision of the UAE and the group’s de facto leader Saudi Arabia have simmered for years.
According to a filing with the Securities and Exchange Commission dated April 28, 2026, Goldstein Advisors acquired 279,496 additional shares of VictoryShares Core Plus Bond ETF (NASDAQ:UBND) . The estimated transaction value is $6.15 million, based on the average closing price during the quarter. The fund’s quarter-end position value increased by $5.78 million, a figure that incorporates both sha...
According to a filing with the Securities and Exchange Commission dated April 28, 2026, Goldstein Advisors acquired 279,496 additional shares of VictoryShares Core Plus Bond ETF (NASDAQ:UBND) . The estimated transaction value is $6.15 million, based on the average closing price during the quarter. The fund’s quarter-end position value increased by $5.78 million, a figure that incorporates both share purchases and price fluctuations. VictoryShares Core Plus Bond ETF (UBND) offers institutional investors access to a diversified portfolio of primarily investment-grade fixed income securities, with a flexible mandate to allocate a portion to high-yield bonds . The fund seeks to optimize yield and risk-adjusted returns through active management and disciplined portfolio construction. Its structure as an ETF provides transparency, liquidity, and cost efficiency, making it a competitive choice for core bond allocations within diversified portfolios. Goldstein’s Q1 2026 purchase of additional shares in VictoryShares Core Plus Bond ETF appears to be a minor portfolio adjustment, since its position moved from No. 8 in Q4 2025 to No. 7 in the most recent quarter. Judging by its largest holdings, the fund is building its portfolio around diversified ETFs that include both equities and fixed income, suggesting a balanced strategy. Continue reading
Earnings Call Insights: OPKO Health (OPK) Q1 2026 Management view Dr. Phillip Frost (Chairman & CEO) said OPKO’s “particular emphasis” in Q1 was “advancing our ModeX product development pipeline,” adding that “ModeX now has 5 programs in the clinic” and that OPKO “dosed our first subjects in the Phase I clinical trial of MDX2301” and “announced the dosing of the first patient” for MDX2003. Dr. Phi...
Earnings Call Insights: OPKO Health (OPK) Q1 2026 Management view Dr. Phillip Frost (Chairman & CEO) said OPKO’s “particular emphasis” in Q1 was “advancing our ModeX product development pipeline,” adding that “ModeX now has 5 programs in the clinic” and that OPKO “dosed our first subjects in the Phase I clinical trial of MDX2301” and “announced the dosing of the first patient” for MDX2003. Dr. Phillip Frost (Chairman & CEO) described partnerships as a funding lever, saying the Regeneron collaboration “is a good source of nondilutive capital,” and stating, “The potential total value of the Regeneron collaboration exceeds $1 billion in milestones plus future royalties.” Dr. Elias Zerhouni (President & Vice Chairman) highlighted upcoming catalysts and timelines, saying Merck “expect[s] … the data needed to inform a Phase II design by the end of this year” with “initiation of a Phase II clinical study anticipated next year,” while OPKO expects to present “Phase Ia data” for MDX2001 “in the second half of this year.” Adam Logal (Senior VP, CFO, Chief Accounting Officer & Treasurer) emphasized liquidity and capital return, saying, “We ended the quarter with … over $341 million in cash, cash equivalents and restricted cash,” and adding, “as of the end of Q1, we had approximately $108 million authorized to repurchase shares of our common stock.” Outlook Adam Logal (Senior VP, CFO, Chief Accounting Officer & Treasurer) guided Q2 2026 total revenue to “between $127 million to $132 million,” with “revenue of services from $72 million to $76 million,” “Pharmaceutical product revenue of $38 million to $42 million,” and “IP and other revenue … between $15 million to $19 million, including the Pfizer profit share of $6 million to $8 million.” Adam Logal (Senior VP, CFO, Chief Accounting Officer & Treasurer) guided Q2 total costs and expenses to “between $180 million and $190 million,” and said OPKO expects “R&D to become between $32 million and $38 million, partially offset by $5 ...